Skip to main content

Table 2 Correlation of IL2RA mRNA expressions with cytogenetical and genetic abnormalities in AML

From: High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia

Cytogenetical and genetic abnormalities N/Total Low IL2RA mRNA expression High IL2RA mRNA expression p-value
CBF 54/239 45/191 9/48 0.565
Intermediate-risk 148/239 118/191 30/48 1.000
Poor-risk 39/239 29/191 9/48 0.505
t(8;21);RUNX1-RUNX1T1 37/239 29/191 8/48 0.824
inv(16) or t(16;16);CBFB-MYH11 17/239 16/191 1/48 0.207
t(9;11);MLLT3-KMT2A 4/239 4/191 0/48 0.586
t(6;9);DEK-NUP214 3/239 2/191 1/48 0.491
inv(3) or t(3;3);GATA2, MECOM 6/239 4/191 2/48 0.347
11q23; non t(9;11) 3/239 3/191 0/48 0.700
t(16;21);FUS-ERG 2/239 0/191 2/48 0.040
−7/7q− 11/239 7/191 4/48 0.238
−5/5q− 5/239 4/191 1/48 1.000
Complex 17/239 12/191 5/48 0.346
Normal karyotype 113/239 92/191 21/48 0.630
Trisomy 17/239 13/191 4/48 0.754
FLT3-ITD+ 38/192 17/151 21/41 < 0.001
NPM1+ 36/192 28/151 8/41 1.000
NPM1+FLT3-ITD 22/192 22/151 0/41 0.005
CEBPADM+ 19/192 18/151 1/41 0.082
c-KIT D816V+ 7/192 6/151 1/41 1.000
  1. N: number